Eliciting B cell immunity against infectious diseases using nanovaccines
Open accessAbstract
Infectious diseases, including the coronavirus disease 2019 (COVID-19) pandemic that has brought the world to a standstill, are emerging at an unprecedented rate with a substantial impact on public health and global economies. For many life-threatening global infectious diseases, such as human immunodeficiency virus (HIV) infection, malaria and influenza, effective vaccinations are still lacking. There are numerous roadblocks to developing new vaccines, including a limited understanding of immune correlates of protection to these global infections. To induce a reproducible, strong immune response against difficult pathogens, sophisticated nanovaccine technologies are under investigation. In contrast to conventional vaccines, nanovaccines provide improved access to lymph nodes, optimal packing and presentation of antigens, and induction of a persistent immune response. This Review provides a perspective on the global trends in emerging nanoscale vaccines for infectious diseases and describes the biological, experimental and logistical problems associated with their development, and how immunoengineering can be leveraged to overcome these challenges.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The broadly neutralizing monoclonal antibodies VRC01 neutralize 98% of HIV strains and prevent transmission of antibody-sensitive strains with 75.4% efficacy.
“Notably, the broadly neutralizing mAbs, VRC01, have recently gained attention thanks to their ability to neutralize 98% of HIV strains167 and prevent transmission of antibody-sensitive strains with 75.4% efficacy168.”
From mRNA vaccines for infectious diseases: principles, delivery and clinical translation (2021) · cites this paper as [167]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667 · see citing works
Exploiting lymphatic transport and complement activation in nanoparticle vaccines
Reddy, S. T., van der Vlies, A. J., Simeoni, E., Angeli, V., Randolph, G. J., O’Neil, C. P., Lee, L. K., Swartz, M. A., & Hubbell, J. A. (2007) · Nature Biotechnology · doi:10.1038/nbt1332 · Cited by 1,355 · see citing works
Dawood, F. S., Iuliano, A., Reed, C., Meltzer, M., Shay, D., Cheng, P.-Y., Bandaranayake, D., Breiman, R., Brooks, W. A., Buchy, P., et al. (2012) · Lancet. Infectious Diseases (Print) · doi:10.1016/s1473-3099(12)70121-4 · Cited by 1,294 · see citing works
SARS-CoV-2 Vaccines: Status Report
Amanat, F., & Krammer, F. (2020) · Immunity · doi:10.1016/j.immuni.2020.03.007 · Cited by 1,120 · see citing works
Germinal Center B Cell Dynamics
Mesin, L., Ersching, J., & Victora, G. D. (2016) · Immunity · doi:10.1016/j.immuni.2016.09.001 · Cited by 977 · see citing works
Programming the magnitude and persistence of antibody responses with innate immunity
Kasturi, S. P., Skountzou, I., Albrecht, R. A., Koutsonanos, D., Tang, H., Nakaya, H. I., Ravindran, R., Stewart, S. M., Alam, M. S., Kwissa, M., et al. (2011) · Nature · doi:10.1038/nature09737 · Cited by 970 · see citing works
Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies
Kanekiyo, M., Wei, C., Yassine, H. M., McTamney, P. M., Boyington, J. C., Whittle, J. R. R., Rao, S. S., Kong, W., Wang, L., & Nabel, G. J. (2013) · Nature · doi:10.1038/nature12202 · Cited by 887 · see citing works
Rational HIV Immunogen Design to Target Specific Germline B Cell Receptors
Jardine, J., Julien, J.-P., Menis, S., Ota, T., Kalyuzhniy, O., McGuire, A., Sok, D., Huang, P.-S., MacPherson, S., Jones, M., et al. (2013) · Science · doi:10.1126/science.1234150 · Cited by 770 · see citing works
Sixt, M., Kanazawa, N., Selg, M., Samson, T., Roos, G., Reinhardt, D. P., Pabst, R., Lutz, M. B., & Sorokin, L. M. (2005) · Immunity · doi:10.1016/j.immuni.2004.11.013 · Cited by 749 · see citing works
Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19
Kaneko, N., Kuo, H.-H., Boucau, J., Farmer, J. R., Allard-Chamard, H., Mahajan, V. S., Piechocka-Trocha, A., Lefteri, K., Osborn, M., Bals, J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.025 · Cited by 734 · see citing works
Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection
Yassine, H. M., Boyington, J. C., McTamney, P. M., Wei, C., Kanekiyo, M., Kong, W., Gallagher, J. R., Wang, L., Zhang, Y., Joyce, M. G., et al. (2015) · Nature Medicine · doi:10.1038/nm.3927 · Cited by 702 · see citing works
In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles
Reddy, S. T., Rehor, A., Schmoekel, H. G., Hubbell, J. A., & Swartz, M. A. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.01.006 · Cited by 680 · see citing works
Clonal selection in the germinal centre by regulated proliferation and hypermutation
Gitlin, A. D., Shulman, Z., & Nussenzweig, M. C. (2014) · Nature · doi:10.1038/nature13300 · Cited by 577 · see citing works
Antibiotics-Driven Gut Microbiome Perturbation Alters Immunity to Vaccines in Humans
Hagan, T., Cortese, M., Rouphael, N., Boudreau, C., Linde, C., Maddur, M. S., Das, J., Wang, H., Guthmiller, J., Zheng, N.-Y., et al. (2019) · Cell · doi:10.1016/j.cell.2019.08.010 · Cited by 572 · see citing works
Proof of principle for epitope-focused vaccine design
Correia, B. E., Bates, J. T., Loomis, R. J., Baneyx, G., Carrico, C., Jardine, J. G., Rupert, P., Correnti, C., Kalyuzhniy, O., Vittal, V., et al. (2014) · Nature · doi:10.1038/nature12966 · Cited by 555 · see citing works
Tseng, C.-T. K., Sbrana, E., Iwata‐Yoshikawa, N., Newman, P. C., Garron, T. M., Atmar, R. L., Peters, C. J., & Couch, R. B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035421 · Cited by 555 · see citing works
Oh, J. Z., Ravindran, R., Chassaing, B., Carvalho, F. A., Maddur, M. S., Bower, M., Hakimpour, P., Gill, K. P., Nakaya, H. I., Yarovinsky, F., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.08.009 · Cited by 541 · see citing works
The potential danger of suboptimal antibody responses in COVID-19
Iwasaki, A., & Yang, Y.-X. (2020) · Nature reviews. Immunology · doi:10.1038/s41577-020-0321-6 · Cited by 510 · see citing works
B-cell–lineage immunogen design in vaccine development with HIV-1 as a case study
Haynes, B. F., Kelsoe, G. H., Harrison, S. C., & Kepler, T. B. (2012) · Nature Biotechnology · doi:10.1038/nbt.2197 · Cited by 481 · see citing works
Bolles, M., Deming, D., Long, K., Agnihothram, S., Whitmore, A., Ferris, M., Funkhouser, W., Gralinski, L., Totura, A., Heise, M., et al. (2011) · Journal of Virology · doi:10.1128/jvi.06048-11 · Cited by 477 · see citing works
Visualizing antibody affinity maturation in germinal centers
Tas, J. M. J., Mesin, L., Pasqual, G., Targ, S., Jacobsen, J. T., Mano, Y. M., Chen, C. S., Weill, J., Reynaud, C., Browne, E. P., et al. (2016) · Science · doi:10.1126/science.aad3439 · Cited by 464 · see citing works
Potent protection against H5N1 and H7N9 influenza via childhood hemagglutinin imprinting
Gostic, K. M., Ambrose, M. R., Worobey, M., & Lloyd‐Smith, J. O. (2016) · Science · doi:10.1126/science.aag1322 · Cited by 464 · see citing works
Feldman, R. A., Fuhr, R., Smolenov, I., (Mick) Ribeiro, A., Panther, L., Watson, M., Senn, J. J., Smith, M., Almarsson, Ӧ., Pujar, H. S., et al. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.04.074 · Cited by 454 · see citing works
HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen
Jardine, J. G., Kulp, D. W., Havenar‐Daughton, C., Sarkar, A., Briney, B. S., Sok, D., Sesterhenn, F., Ereño‐Orbea, J., Kalyuzhniy, O., Deresa, I., et al. (2016) · Science · doi:10.1126/science.aad9195 · Cited by 451 · see citing works
Conduits Mediate Transport of Low-Molecular-Weight Antigen to Lymph Node Follicles
Roozendaal, R., Mempel, T. R., Pitcher, L. A., González, S., Verschoor, A., Mebius, R. E., von Andrian, U. H., & Carroll, M. C. (2009) · Immunity · doi:10.1016/j.immuni.2008.12.014 · Cited by 446 · see citing works
Single-Cell RNA Sequencing of Lymph Node Stromal Cells Reveals Niche-Associated Heterogeneity
Rodda, L. B., Lu, E., Bennett, M. L., Sokol, C. L., Wang, X., Luther, S. A., Barres, B. A., Luster, A. D., Ye, C., & Cyster, J. G. (2018) · Immunity · doi:10.1016/j.immuni.2018.04.006 · Cited by 441 · see citing works
Agarwal, R., Singh, V., Jurney, P., Shi, L., Sreenivasan, S. V., & Roy, K. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1305000110 · Cited by 424 · see citing works
Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen
Jardine, J. G., Ota, T., Sok, D., Pauthner, M. G., Kulp, D. W., Kalyuzhniy, O., Skog, P. D., Thinnes, T. C., Bhullar, D., Briney, B. S., et al. (2015) · Science · doi:10.1126/science.aac5894 · Cited by 420 · see citing works
Recent progress in broadly neutralizing antibodies to HIV
Sok, D., & Burton, D. R. (2018) · Nature Immunology · doi:10.1038/s41590-018-0235-7 · Cited by 406 · see citing works
HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies
Steichen, J. M., Kulp, D. W., Tokatlian, T., Escolano, A., Dosenovic, P., Stanfield, R. L., McCoy, L. E., Ozorowski, G., Hu, X., Kalyuzhniy, O., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.08.016 · Cited by 404 · see citing works
Hydrogels and Scaffolds for Immunomodulation
Singh, A. K., & Peppas, N. A. (2014) · Advanced Materials · doi:10.1002/adma.201402105 · Cited by 358 · see citing works
Self-citationB cell follicles and antigen encounters of the third kind
Cyster, J. G. (2010) · Nature Immunology · doi:10.1038/ni.1946 · Cited by 342 · see citing works
Abbott, R. K., Lee, J. H., Menis, S., Skog, P. D., Rossi, M., Ota, T., Kulp, D. W., Bhullar, D., Kalyuzhniy, O., Havenar‐Daughton, C., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.11.023 · Cited by 340 · see citing works
Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning
Kwong, P. D., Mascola, J. R., & Nabel, G. J. (2013) · Nature reviews. Immunology · doi:10.1038/nri3516 · Cited by 330 · see citing works
Innate immune recognition of glycans targets HIV nanoparticle immunogens to germinal centers
Tokatlian, T., Read, B. J., Jones, C. A., Kulp, D. W., Menis, S., Chang, J. Y. H., Steichen, J. M., Kumari, S., Allen, J. D., Dane, E. L., et al. (2018) · Science · doi:10.1126/science.aat9120 · Cited by 307 · see citing works
Wang, Q., Zhang, L., Kuwahara, K., Li, L., Liu, Z., Li, T., Zhu, H., Liu, J., Xu, Y., Xie, J., et al. (2016) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.6b00006 · Cited by 297 · see citing works
Xu, K. Y., Acharya, P., Kong, R., Cheng, C., Chuang, G., Liu, K., Louder, M. K., O'Dell, S. J., Rawi, R., Sastry, M., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0042-6 · Cited by 284 · see citing works
Liu, W. Y., Fontanet, A. L., Zhang, P., Zhan, L., Xin, Z., Baril, L., Tang, F., Lv, H., & Cao, W. (2006) · The Journal of Infectious Diseases · doi:10.1086/500469 · Cited by 282 · see citing works
Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice
Dosenovic, P., von Boehmer, L., Escolano, A., Jardine, J. G., Freund, N. T., Gitlin, A. D., McGuire, A. T., Kulp, D. W., Oliveira, T. Y., Scharf, L., et al. (2015) · Cell · doi:10.1016/j.cell.2015.06.003 · Cited by 263 · see citing works
Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses
Yang, Z., Werner, H. C., Kong, W., Leung, K., Traggiai, E., Lanzavecchia, A., & Nabel, G. J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409065102 · Cited by 250 · see citing works
Second signals rescue B cells from activation-induced mitochondrial dysfunction and death
Akkaya, M., Traba, J., Roesler, A. S., Miozzo, P., Akkaya, B., Theall, B. P., Sohn, H., Peña, M., Smelkinson, M. G., Kabát, J., et al. (2018) · Nature Immunology · doi:10.1038/s41590-018-0156-5 · Cited by 242 · see citing works
Induction of HIV Neutralizing Antibody Lineages in Mice with Diverse Precursor Repertoires
Tian, M., Cheng, C., Chen, X., Duan, H., Cheng, H.-L., Dao, M. N., Sheng, Z., Kimble, M. T., Wang, L., Lin, S. G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.07.029 · Cited by 228 · see citing works
Wilson, D. S., Hirosue, S., Raczy, M. M., Bonilla-Ramírez, L., Jeanbart, L., Wang, R., Kwissa, M., Franetich, J., Broggi, M. A. S., Diaceri, G., et al. (2019) · Nature Materials · doi:10.1038/s41563-018-0256-5 · Cited by 222 · see citing works
Clinical Outcomes in Young US Adults Hospitalized With COVID-19
Cunningham, J. W., Vaduganathan, M., Claggett, B. L., Jering, K., Bhatt, A. S., Rosenthal, N. A., & Solomon, S. D. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.5313 · Cited by 220 · see citing works
Chambers, B. S., Parkhouse, K., Ross, T. M., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.06.005 · Cited by 205 · see citing works
Kose, N., Fox, J. M., Sapparapu, G., Bombardi, R., Tennekoon, R. N., de Silva, A. D., Elbashir, S. M., Theisen, M. A., Humphris-Narayanan, E., Ciaramella, G., et al. (2019) · Science Immunology · doi:10.1126/sciimmunol.aaw6647 · Cited by 202 · see citing works
Jaroentomeechai, T., Stark, J. C., Natarajan, A., Glasscock, C. J., Yates, L. E., Hsu, K. J., Mrksich, M., Jewett, M. C., & DeLisa, M. P. (2018) · Nature Communications · doi:10.1038/s41467-018-05110-x · Cited by 201 · see citing works
Zhang, Y.-N., Lazarovits, J., Poon, W., Ouyang, B., Nguyen, L. N. M., Kingston, B. R., & Chan, W. C. W. (2019) · Nano Letters · doi:10.1021/acs.nanolett.9b02834 · Cited by 201 · see citing works
Double-layered protein nanoparticles induce broad protection against divergent influenza A viruses
Deng, L., Mohan, T., Chang, T. Z., Gonzalez, G. X., Wang, Y., Kwon, Y., Kang, S., Compans, R. W., Champion, J. A., & Wang, B. (2018) · Nature Communications · doi:10.1038/s41467-017-02725-4 · Cited by 190 · see citing works
Early estimates of seasonal influenza vaccine effectiveness - United States, January 2015.
Flannery, B. L., Clippard, J. R., Zimmerman, R. K., et al. (2015) · PubMed · Cited by 189 · see citing works
Béguelin, W., Rivas, M. A., Calvo, M. T., Teater, M. R., Purwada, A., Redmond, D., Shen, H., Challman, M. F., Elemento, O., Singh, A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01029-x · Cited by 183 · see citing works
Self-citationEarly Estimates of Seasonal Influenza Vaccine Effectiveness—United States, January 2013
(2013) · American Journal of Transplantation · doi:10.1111/ajt.12203 · Cited by 178 · see citing works
Havenar‐Daughton, C., Carnathan, D. G., de la Peña, A. T., Pauthner, M. G., Briney, B. S., Reiss, S. M., Wood, J., Kaushik, K., van Gils, M. J., Rosales, S. L., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.10.085 · Cited by 175 · see citing works
Targeted selection of HIV-specific antibody mutations by engineering B cell maturation
Saunders, K. O., Wiehe, K. J., Tian, M., Acharya, P., Bradley, T., Alam, S. M., Go, E. P., Scearce, R. M., Sutherland, L. L., Henderson, R. C., et al. (2019) · Science · doi:10.1126/science.aay7199 · Cited by 171 · see citing works
Programmable multistage drug delivery to lymph nodes
Schudel, A., Chapman, A. P., Yau, M., Higginson, C. J., Francis, D. M., Manspeaker, M. P., Avecilla, A. R. C., Rohner, N. A., Finn, M. G., & Thomas, S. N. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-0679-4 · Cited by 153 · see citing works
Swartz, M. A., Hubbell, J. A., & Reddy, S. T. (2008) · Seminars in Immunology · doi:10.1016/j.smim.2007.11.007 · Cited by 148 · see citing works
Kasturi, S. P., Rasheed, M. A. U., Havenar‐Daughton, C., Pham, M., Legere, T. H., Sher, Z. J., Kovalenkov, Y. O., Gumber, S., Huang, J. Y., Gottardo, R., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abb1025 · Cited by 142 · see citing works
Wiehe, K. J., Bradley, T., Meyerhoff, R. R., Hart, C., Williams, W. B., Easterhoff, D., Faison, W. J., Kepler, T. B., Saunders, K. O., Alam, S. M., et al. (2018) · Cell Host & Microbe · doi:10.1016/j.chom.2018.04.018 · Cited by 132 · see citing works
Immune perturbations in HIV-1–infected individuals who make broadly neutralizing antibodies
Moody, M. A., Pedroza‐Pacheco, I., Vandergrift, N., Chui, C., Lloyd, K. E., Parks, R., Soderberg, K. A., Ogbe, A., Cohen, M. S., Liao, H., et al. (2016) · Science Immunology · doi:10.1126/sciimmunol.aag0851 · Cited by 128 · see citing works
Purwada, A., & Singh, A. (2016) · Nature Protocols · doi:10.1038/nprot.2016.157 · Cited by 101 · see citing works
Self-citationPrevo, R., Banerji, S., Ni, J., & Jackson, D. G. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m406897200 · Cited by 94 · see citing works
Winarski, K. L., Tang, J., Klenow, L., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1821317116 · Cited by 85 · see citing works
Design of a broadly reactive Lyme disease vaccine
Kamp, H. D., Swanson, K. A., Wei, R. R., et al. (2020) · npj Vaccines · doi:10.1038/s41541-020-0183-8 · Cited by 84 · see citing works
Multiscale engineering of immune cells and lymphoid organs
Kim, S., Shah, S. B., Graney, P. L., & Singh, A. (2019) · Nature Reviews Materials · doi:10.1038/s41578-019-0100-9 · Cited by 79 · see citing works
Self-citationPurwada, A., Shah, S. B., Béguelin, W., August, A., Melnick, A. M., & Singh, A. K. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.06.034 · Cited by 60 · see citing works
Self-citationEngineering vaccines and niches for immune modulation
Purwada, A., Roy, K., & Singh, A. K. (2014) · Acta Biomaterialia · doi:10.1016/j.actbio.2013.12.036 · Cited by 47 · see citing works
Self-citationMosquera, M. J., Kim, S., Zhou, H., Jing, T. T., Luna, M., Guss, J. D., Reddy, P. M., Lai, K., Leifer, C. A., Brito, I., et al. (2019) · Science Advances · doi:10.1126/sciadv.aav9788 · Cited by 38 · see citing works
Self-citationGraney, P. L., Lai, K., Post, S. E., Brito, I., Cyster, J. G., & Singh, A. K. (2020) · Advanced Functional Materials · doi:10.1002/adfm.202001232 · Cited by 30 · see citing works
Self-citationTowards a universal flu vaccine
Eisenstein, M. S. (2019) · Nature · doi:10.1038/d41586-019-02751-w · Cited by 24 · see citing works
Pulendran, B. (2019) · Science · doi:10.1126/science.aau6975 · Cited by 24 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
mRNA vaccines for infectious diseases: principles, delivery and clinical translation
Chaudhary, N., Weissman, D., & Whitehead, K. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00283-5 · Cited by 1,555 · see citing works
A Comprehensive Review of mRNA Vaccines
Gote, V., Bolla, P. K., Kommineni, N., Butreddy, A., Nukala, P. K., Palakurthi, S. S., & Khan, W. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032700 · Cited by 457 · see citing works
- Authors
- Singh, A.
- Affiliations
- Georgia Institute of Technology (US)
- Corresponding author
- Singh, Ankur
- ORCID
- Singh, Ankur
- Venue
- Nature Nanotechnology
- Published
- 2020-11-16
- Volume
- 16
- Issue
- 1
- Pages
- 16-24
- ISSN
- 1748-3387 (ISSN-L)
- 1748-3395
- PMC
- PMC7855692
- OpenAlex
- W3103525807
- Cited by
- 169
- References
- 70
- Citations by year
- 2026: 18 · 2025: 23 · 2024: 28 · 2023: 40 · 2022: 36 · 2021: 23 · 2020: 1
- FWCI
- 2.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Nature Nanotechnology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (5R01AI132738-03)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- nanovaccines, B-cell immunity, infectious disease vaccines, immunoengineering, antigen presentation, correlates of protection, HIV, malaria, influenza, COVID-19 pandemic
- MeSH terms
- Animals, B-Lymphocytes, Communicable Diseases, Humans, Lymph Nodes, Mutation, Vaccines, Antigen Presentation, Antibody-Dependent Enhancement, Nanoparticles, Antibodies, Neutralizing, Microbiota
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review